OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the stock.

Separately, Needham & Company LLC reissued a buy rating and issued a $4.25 price objective on shares of OncoCyte in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, OncoCyte presently has a consensus rating of Hold and a consensus target price of $4.06.

OncoCyte Price Performance

Shares of NASDAQ:OCX opened at $3.05 on Wednesday. The business’s 50 day simple moving average is $3.07 and its 200-day simple moving average is $2.93. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.34.

OncoCyte (NASDAQ:OCX) last posted its earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The firm had revenue of $0.10 million for the quarter.

Insiders Place Their Bets

In related news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of OncoCyte stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the transaction, the insider now directly owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CFO Andrea S. James bought 33,670 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were purchased at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was acquired at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the acquisition, the insider now directly owns 6,244,405 shares in the company, valued at $18,420,994.75. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 1.94% of the stock is currently owned by company insiders.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.